Advertisement
Advertisement
U.S. Markets close in 30 mins
Advertisement
Advertisement
Advertisement
Advertisement

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7512+0.0512 (+1.90%)
As of 03:30PM EDT. Market open.
Advertisement
Full screen
Loading interactive chart...
  • Motley Fool

    Chimerix (CMRX) Q2 2022 Earnings Call Transcript

    With me on today's call are president and chief executive officer, Mike Sherman; chief medical officer, Allen Melemed; chief financial and business officer, Mike Andriole; chief science officer, Randall Lanier; and our chief technology officer of Imipridones, Josh Allen. Before we begin, I'd like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors.

  • GlobeNewswire

    Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update

    – ONC201 Phase 3 ACTION Study Planned to Initiate This Year – –~$32M in Revenue from International TEMBEXA Agreements Recently Recognized– – U.S. Anti-Trust Clearance Obtained for Sale of TEMBEXA to Emergent BioSolutions – – Conference Call at 4:30 p.m. ET Today – DURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today repor

  • GlobeNewswire

    Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs

    Brings 30 Years of Experience as a Former Endocyte and Novartis Regulatory ExecutiveDURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today appointed Christopher L. Jordan as Vice President, Regulatory Affairs. “We are pleased to announce the addition of Christopher Jordan to our leadership team as VP of Regulatory Affairs.

Advertisement
Advertisement